Literature DB >> 11518758

Impaired synthesis of DHA in patients with X-linked retinitis pigmentosa.

D R Hoffman1, J C DeMar, W C Heird, D G Birch, R E Anderson.   

Abstract

Many patients with X-linked retinitis pigmentosa (XLRP) have lower than normal blood levels of the long-chain polyunsaturated omega3 fatty acid docosahexaenoic acid (DHA; 22:6omega3). This clinical trial was designed to test whether down-regulation of DHA biosynthesis might be responsible for these reduced DHA levels. DHA biosynthesis was assessed in five severely affected patients with XLRP and in five age-matched controls by quantifying conversion of [U-(13)C]alpha-linolenic acid (alpha-LNA) to [(13)C]DHA. Following oral administration of [U-(13)C]alpha-LNA, blood samples were collected at designated intervals for 21 days and isotopic enrichment of all omega3 fatty acids was determined by gas chromatography/mass spectroscopy. Activity of each metabolic step in the conversion of alpha-LNA to DHA was determined by comparison of the ratios of the integrated concentration of (13)C-product to (13)C-precursor in plasma total lipid fractions. The ratio of [(13)C]DHA to [(13)C]18:3omega3 (the entire pathway) and that of [(13)C]20:5omega3 to [(13)C]20:4omega3 (Delta(5)-desaturase) were significantly lower in patients versus controls (P = 0.03 and 0.05, respectively). The estimated biosynthetic rates of [(13)C]20:5omega3, [(13)C]22:5omega3, [(13)C]24:5omega3, [(13)C]24:6omega3, and [(13)C]22:6omega3 were significantly lower in XLRP patients (42%, 43%, 31%, 18%, and 32% of control values, respectively; P < 0.04), supporting down-regulation of Delta(5)-desaturase in XLRP. The disappearance of (13)C-labeled fatty acids from plasma was not greater in XLRP patients compared with controls, suggesting that XLRP was not associated with increased rates of fatty acid oxidation or other routes of catabolism.Thus, despite individual variation among both patients and controls, the data are consistent with a lower rate of Delta(5)-desaturation, suggesting that decreased biosynthesis of DHA may contribute to lower blood levels of DHA in patients with XLRP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11518758

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  15 in total

1.  Photoreceptor outer segment phagocytosis attenuates oxidative stress-induced apoptosis with concomitant neuroprotectin D1 synthesis.

Authors:  Pranab K Mukherjee; Victor L Marcheselli; Juan Carlos de Rivero Vaccari; William C Gordon; Fannie E Jackson; Nicolas G Bazan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

2.  Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases.

Authors:  Nicolas G Bazan; Miguel F Molina; William C Gordon
Journal:  Annu Rev Nutr       Date:  2011-08-21       Impact factor: 11.848

3.  Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; Rand Spencer; Gary E Fish; N Shirlene Pearson; Yi-Zhong Wang; Martin Klein; Alison Takacs; Kirsten G Locke; David G Birch
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

4.  Changes of the transcriptional and fatty acid profiles in response to n-3 fatty acids in SH-SY5Y neuroblastoma cells.

Authors:  Bénédicte Langelier; Jean-Marc Alessandri; Marie-Hélène Perruchot; Philippe Guesnet; Monique Lavialle
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

5.  Syntaxin 3 and SNAP-25 pairing, regulated by omega-3 docosahexaenoic acid, controls the delivery of rhodopsin for the biogenesis of cilia-derived sensory organelles, the rod outer segments.

Authors:  Jana Mazelova; Nancy Ransom; Lisa Astuto-Gribble; Michael C Wilson; Dusanka Deretic
Journal:  J Cell Sci       Date:  2009-05-19       Impact factor: 5.285

6.  Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial.

Authors:  Dianna K Hughbanks-Wheaton; David G Birch; Gary E Fish; Rand Spencer; N Shirlene Pearson; Alison Takacs; Dennis R Hoffman
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-11       Impact factor: 4.799

7.  Haploinsufficiency of RanBP2 is neuroprotective against light-elicited and age-dependent degeneration of photoreceptor neurons.

Authors:  K-in Cho; H Yi; A Yeh; N Tserentsoodol; L Cuadrado; K Searle; Y Hao; P A Ferreira
Journal:  Cell Death Differ       Date:  2008-10-24       Impact factor: 15.828

Review 8.  Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease.

Authors:  Nicolas G Bazan
Journal:  J Lipid Res       Date:  2008-11-18       Impact factor: 5.922

9.  Dietary supplement enriched in antioxidants and omega-3 protects from progressive light-induced retinal degeneration.

Authors:  Khaoula Ramchani-Ben Othman; Christine Cercy; Mohamed Amri; Michel Doly; Isabelle Ranchon-Cole
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

Review 10.  Systematic Review of Randomized Clinical Trials on Safety and Efficacy of Pharmacological and Nonpharmacological Treatments for Retinitis Pigmentosa.

Authors:  Marta Sacchetti; Flavio Mantelli; Daniela Merlo; Alessandro Lambiase
Journal:  J Ophthalmol       Date:  2015-08-03       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.